NEWS DETAIL

Episil (Oral Liquid) Launched in Japan

Tokyo, Japan, May 16th, 2018 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that episil® (SP-03) has been launched in Japan by its commercialization and promotion partner, Meiji Seika Pharma Co., Ltd.. In 2015 Solasia acquired the commercial rights for episil® oral liquid in Japan from Camurus AB and has successfully registered the product during 2017. **************************************************************************** 


About episil® oral liquid: 


episil® oral liquid represents a unique and innovative concept for local treatment of pain associated with oral mucositis. Developed using the award-winning* Camurus proprietary technology FluidCrystal® , episil® is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive film that mechanically protects the sensitized and sore epithelium of the oral cavity. Clinically demonstrated, episil® has been shown to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours. episil® oral liquid is the only product for oral mucositis that is supplied as a ready-to-use, pocket-sized device helping patients maintain their quality of life while undergoing cancer therapy. episil® was first launched in Europe and is today commercially available in a number of countries, including the US. episil® oral liquid is a CE-marked medical device class 1 in Europe and a 510k registered medical device in the US. 


About Solasia: 


Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers. Additional information is available at http://www.solasia.co.jp/en/ %uFF08Contact%uFF09 Solasia Pharma K.K. Rie Toyoda Investor Relations 81-3-5843-8049 [email protected]